white papers

    From consumer gadgets to medical devices

    From consumer gadgets to medical devices
    Henk Grootveld - Head of Trends Investing

    Henk Grootveld

    Head of Trends Investing

     

     

    The distinction between consumer and healthcare devices is becoming less pronounced in light of a recent trend whereby more consumers are using medically-proven health monitoring tools, and more non-patients are using medical devices. Investors in this market should be aware of how competition is developing.

     

    Need to know

    • Measuring health conditions is no longer the exclusive remit of the doctor or hospital
    • Our Global HealthTech strategy harnesses the quantified-self trend through its focus on companies digitalising the healthcare sector
    • Smart watches - still seen by most as just consumer gadgets - have made the first step into becoming an official medical device

     

    MedTech becomes mainstream

    The first MedTech companies, which stands for medical technology companies, are now crossing over to the consumer side, becoming more widely available and commonplace. One example is Masimo1 - a market leader in pulse oximetry, which is a non-invasive technology that is used to measure all sorts of vital signs like heart rhythm and oxygen levels within the blood and is used in most emergency rooms around the world to constantly monitor patients. At the start of 2022, the company announced the acquisition of Sound United1, a consumer electronics company focused on high-end loudspeakers and wireless headsets. Following the acquisition, Masimo says it wants to follow the patient from the hospital to the home and introduce new quantified self-devices like smart watches and over-the-counter hearing aids, which will soon be available to US consumers without the need to consult an audiologist.

    The move from Masimo proved quite a shock for its MedTech investors as it lost 40% of its market capitalisation in the days following the announcement.  Sound United cost Masimo roughly USD 1 billion and the company has lost more than USD 5 billion in market capitalisation, despite the fact that the deal looks financially sound, with an expected 8-10% return on invested capital and more than 20% accretion to their earnings per share. Investors were simply shocked and seemingly unable to grasp that quantified self has outgrown the hype and has become a real trend and Masimo is ready to take on Apple, Garmin, Fitbit and Samsung.

     

    Apple takes a bite

    Measuring health conditions is no longer the exclusive remit of the doctor or hospital. Consumer products are making inroads into the medical technology space. The seventh version of the Apple Watch1 has the capacity to warn about abnormal heart rates, detect falls, do electrocardiogram (ECG) readings and track blood oxygen levels. This first functionality, to warn about abnormal heart rates and detect a condition called atrial fibrillation, has been approved by Food and Drug Administration (FDA) in the US, as has the ability to monitor Parkinson’s disease. With FDA approval, smart watches - still seen by most as just consumer gadgets - have made the first step into becoming an official medical device.

    In addition to getting health monitors medically approved, Apple also got FDA approval in 2019 to store electronic health records (EHR) on iPhones. Apple claims this will enable the company to centralise all health data in one place - the personal smart phone of a patient - instead of having incomplete files spread across different healthcare providers, payers and suppliers. Of course, Apple would like to combine these official medical records with the all the monitoring data collected by their smart watch in order to become a one-stop digital lifestyle coach.  Knowing that this digital coach also has access to your GPS data, future alerts might not only be on the need to exercise more often, but also on the need to skip a weekly stop by a beloved fast-food restaurant.

     

    Big Tech

    We expect other Big Tech companies to try to follow the Apple lead. Particularly Alphabet1, the company behind search engine Google and the Android operating system for smart phones.  Alphabet acquired the company Fitbit1 in 2020 and recently announced a partnership with Electronic Health Record (EHR) vendor Meditech, a major player in the hospital software space. The company has also launched a booking tool for healthcare appointments, with healthcare providers like CVS MinuteClinic.

    Our Global HealthTech strategy harnesses the quantified-self trend through its focus on companies digitalising the healthcaresector to make it more efficient, connected and focused on prevention.

    To find out more about the quantified self and the investment implications, read the full paper: ‘Quantified Self: from hype to trend’.


     

    Source.

    [1] Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold or directly invest in the company or securities. It should not be assumed that the recommendations made in the future will be profitable or will equal the performance of the securities discussed in this document

    important information.

    This document is issued by Lombard Odier Asset Management (Europe) Limited, authorised and regulated by the Financial Conduct Authority (the “FCA”), and entered on the FCA register with registration number 515393.
    Lombard Odier Investment Managers (“LOIM”) is a trade name.
    This document is provided for information purposes only and does not constitute an offer or a recommendation to purchase or sell any security or service. It is not intended for distribution, publication, or use in any jurisdiction where such distribution, publication, or use would be unlawful. This material does not contain personalized recommendations or advice and is not intended to substitute any professional advice on investment in financial products. Before entering into any transaction, an investor should consider carefully the suitability of a transaction to his/her particular circumstances and, where necessary, obtain independent professional advice in respect of risks, as well as any legal, regulatory, credit, tax, and accounting consequences. This document is the property of LOIM and is addressed to its recipient exclusively for their personal use. It may not be reproduced (in whole or in part), transmitted, modified, or used for any other purpose without the prior written permission of LOIM. This material contains the opinions of LOIM, as at the date of issue.
    Neither this document nor any copy thereof may be sent, taken into, or distributed in the United States of America, any of its territories or possessions or areas subject to its jurisdiction, or to or for the benefit of a United States Person. For this purpose, the term "United States Person" shall mean any citizen, national or resident of the United States of America, partnership organized or existing in any state, territory or possession of the United States of America, a corporation organized under the laws of the United States or of any state, territory or possession thereof, or any estate or trust that is subject to United States Federal income tax regardless of the source of its income.
    Source of the figures: Unless otherwise stated, figures are prepared by LOIM.
    Although certain information has been obtained from public sources believed to be reliable, without independent verification, we cannot guarantee its accuracy or the completeness of all information available from public sources.
    Views and opinions expressed are for informational purposes only and do not constitute a recommendation by LOIM to buy, sell or hold any security. Views and opinions are current as of the date of this presentation and may be subject to change. They should not be construed as investment advice.
    No part of this material may be (i) copied, photocopied or duplicated in any form, by any means, or (ii) distributed to any person that is not an employee, officer, director, or authorised agent of the recipient, without Lombard Odier Asset Management (Europe) Limited prior consent. In the United Kingdom, this material is a marketing material and has been approved by Lombard Odier Asset Management (Europe) Limited  which is authorized and regulated by the FCA. ©2022 Lombard Odier IM. All rights reserved